Immuneering (IMRX) News Today $3.39 -0.20 (-5.57%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.38 -0.02 (-0.44%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Immuneering Corporation (NASDAQ:IMRX) CEO Acquires $10,089.30 in StockJuly 4 at 8:48 AM | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Purchases 2,985 SharesJuly 3 at 11:57 AM | marketbeat.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) CEO Buys 7,015 Shares of StockJuly 3 at 11:57 AM | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall Purchases 9,500 SharesJuly 1, 2025 | insidertrades.comThomas J. Schall Purchases 9,500 Shares of Immuneering Corporation (NASDAQ:IMRX) StockJune 30, 2025 | marketbeat.comAnalysts Set Immuneering Corporation (NASDAQ:IMRX) PT at $13.25June 26, 2025 | americanbankingnews.comImmuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Acquires 6,007 SharesJune 25, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Insider Brett Matthew Hall Purchases 6,007 SharesJune 24, 2025 | marketbeat.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) Insider Buys 7,415 Shares of StockJune 24, 2025 | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) Director Peter Feinberg Buys 25,000 SharesJune 23, 2025 | marketbeat.comImmuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 SharesJune 21, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJune 21, 2025 | marketbeat.comWe're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn RateJune 20, 2025 | finance.yahoo.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) CEO Purchases 21,000 Shares of StockJune 20, 2025 | marketbeat.comPre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIOJune 19, 2025 | nasdaq.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Acquires 40,485 Shares of StockJune 19, 2025 | insidertrades.comImmuneering Corporation (NASDAQ:IMRX) Director Acquires $89,471.85 in StockJune 18, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Price Target Raised to $10.00June 18, 2025 | marketbeat.comChardan Capital Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)June 18, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLCJune 18, 2025 | marketbeat.comImmuneering Corporation to Host Conference Call for Phase 2a Clinical Trial Update on IMM-1-104 in Pancreatic CancerJune 18, 2025 | nasdaq.comImmuneering stock rises after positive pancreatic cancer trial dataJune 17, 2025 | investing.comImmuneering Shares Climb on Promising Pancreatic Cancer Trial ResultsJune 17, 2025 | msn.comImmuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer PatientsJune 17, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Short Interest Up 39.9% in MayJune 16, 2025 | marketbeat.comImmuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025June 16, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLCJune 12, 2025 | marketbeat.comImmuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLCJune 5, 2025 | marketbeat.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.7%June 2, 2025 | marketbeat.comImmuneering to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comImmuneering Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 5, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Short Interest UpdateMay 2, 2025 | marketbeat.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.com177,377 Shares in Immuneering Co. (NASDAQ:IMRX) Bought by Rockefeller Capital Management L.P.April 26, 2025 | marketbeat.comImmuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comChardan Capital Comments on Immuneering FY2025 EarningsMarch 28, 2025 | marketbeat.comImmuneering's (IMRX) Buy Rating Reiterated at Chardan CapitalMarch 25, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given Buy Rating at Needham & Company LLCMarch 22, 2025 | marketbeat.comImmuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 21, 2025 | finanznachrichten.deImmuneering (NASDAQ:IMRX) Issues Earnings ResultsMarch 21, 2025 | marketbeat.comImmuneering Corporation Announces Grant of Inducement AwardMarch 21, 2025 | globenewswire.comImmuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 21, 2025 | finanznachrichten.deImmuneering appoints Matushansky as Chief Medical OfficerMarch 21, 2025 | markets.businessinsider.comImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comImmuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 20, 2025 | globenewswire.comImmuneering management to meet with OppenheimerMarch 7, 2025 | markets.businessinsider.comImmuneering Slides As Insider Purchases Lose Another US$186kMarch 6, 2025 | finance.yahoo.comImmuneering Co. (NASDAQ:IMRX) Receives Average Recommendation of "Hold" from BrokeragesFebruary 28, 2025 | marketbeat.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on FridayFebruary 28, 2025 | marketbeat.comImmuneering and Regeneron partner on lung cancer trialFebruary 6, 2025 | msn.com Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Media Mentions By Week IMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼1.560.58▲Average Medical News Sentiment IMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼82▲IMRX Articles Average Week Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCYC News MNMD News VALN News ZVRA News KURA News TYRA News BCAX News ABVX News SEPN News ORGO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
